The Moscow Region Commercial Court has ordered pharmaceutical companies ViiV Healthcare and Shionogi to grant Biokhimik, part of the Promomed Group, a non-exclusive licence covering two Eurasian patents and one Russian national patent related to cabotegravir. According to Pharmvestnik, the ruling was issued on 20 October 2026. It has not yet entered into force and may be appealed within one
Human papillomavirus (HPV) remains one of the leading causes of preventable cancers, including cervical cancer. However, even though we have effective mechanisms to prevent cervical cancer—such as the WHO global strategy to eliminate it—this disease still remains a public health challenge.
On January 28, 14:00–15:30 CET, Treatment Action Group (TAG) will host the online webinar “What Could Go Right? Partnering with Communities and Civil Society for New TB Vaccines” on the role of communities, NGOs, and civil society in preparing for the introduction of new tuberculosis (TB) vaccines. You can register for the webinar via the link.
The World Health Organization (WHO) has published a report titled “Catalysing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents.” The document was prepared by the Working Group on Financing and Access of the TB Vaccine Accelerator Council.
On October 29, 2025, the Board of the Eurasian Economic Commission (EEC) approved for signature a new three-year action plan to implement the 2021 Memorandum of Understanding with the World Health Organization’s Regional Office for Europe.
The biopharmaceutical company Bluejay Therapeutics is conducting clinical trials of a novel therapeutic candidate, Brelovitug (BJT-778), developed for the treatment of chronic hepatitis delta (hepatitis D). In 2025, two global Phase III clinical studies — AZURE-1 and AZURE-2 — were launched to evaluate the efficacy and safety of the drug.
On October 14, Brussels hosted a panel discussion titled “Removing Barriers: Ensuring Access to Essential Tuberculosis Medicines in the EU and EEA,” organized by Médecins Sans Frontières (MSF). The event brought together representatives of European institutions, the World Health Organization (WHO), national health authorities, and civil society organizations.
On October 1–2, 2025, the Securing Access through End-to-End Design Workshop took place at the Global Health Campus in Geneva. The event was organized by Unitaid, Clinton Health Access Initiative (CHAI), the Center for Global Health Policy & Politics at Georgetown University, and Treatment Action Group (TAG).
On October 2–3, 2025, the International Scientific and Practical Conference “Central Asia Free of Tuberculosis: From National Successes to Regional Leadership” is taking place in Almaty, Kazakhstan, with the participation of the ITPC EECA team.
Unitaid, CHAI, Wits RHI, and pharmaceutical company Dr. Reddy’s have signed an agreement aimed at ensuring access to injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in 120 low- and middle-income countries (LMICs) starting in 2027. The annual cost of the drug will be just $40, with the initial oral lead-in regimen priced at no more than $17.
